Cargando…
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study
PURPOSE: Squamous non–small-cell lung cancer (sqNSCLC) is genetically complex with evidence of DNA damage. This phase III study investigated the efficacy and safety of poly (ADP-ribose) polymerase inhibitor veliparib in combination with conventional chemotherapy for advanced sqNSCLC (NCT02106546). P...
Autores principales: | Ramalingam, Suresh S., Novello, Silvia, Guclu, Salih Zeki, Bentsion, Dmitry, Zvirbule, Zanete, Szilasi, Maria, Bernabe, Reyes, Syrigos, Konstantinos, Byers, Lauren Averett, Clingan, Philip, Bar, Jair, Vokes, Everett E., Govindan, Ramaswamy, Dunbar, Martin, Ansell, Peter, He, Lei, Huang, Xin, Sehgal, Vasudha, Glasgow, Jaimee, Bach, Bruce A., Mazieres, Julien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577684/ https://www.ncbi.nlm.nih.gov/pubmed/34436928 http://dx.doi.org/10.1200/JCO.20.03318 |
Ejemplares similares
-
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study
por: You, Benoit, et al.
Publicado: (2023) -
Profile of veliparib and its potential in the treatment of solid tumors
por: Wagner, Lars M
Publicado: (2015) -
Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017) -
Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma
por: Buck, Jessica, et al.
Publicado: (2021) -
Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
por: Werner, Theresa L., et al.
Publicado: (2018)